262 related articles for article (PubMed ID: 29799015)
1. Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.
Latanova AA; Petkov S; Kilpelainen A; Jansons J; Latyshev OE; Kuzmenko YV; Hinkula J; Abakumov MA; Valuev-Elliston VT; Gomelsky M; Karpov VL; Chiodi F; Wahren B; Logunov DY; Starodubova ES; Isaguliants MG
Sci Rep; 2018 May; 8(1):8078. PubMed ID: 29799015
[TBL] [Abstract][Full Text] [Related]
2. Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization.
Starodubova E; Boberg A; Ivanov A; Latyshev O; Petrakova N; Kuzmenko Y; Litvina M; Chernousov A; Kochetkov S; Karpov V; Wahren B; Isaguliants MG
Vaccine; 2010 Feb; 28(8):1975-86. PubMed ID: 20188253
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response.
Starodubova ES; Boberg A; Litvina M; Morozov A; Petrakova NV; Timofeev A; Latyshev O; Tunitskaya V; Wahren B; Isaguliants MG; Karpov VL
Vaccine; 2008 Sep; 26(40):5170-6. PubMed ID: 18468738
[TBL] [Abstract][Full Text] [Related]
4. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
5. Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in a mouse model.
Isaguliants MG; Zuber B; Boberg A; Sjöstrand D; Belikov SV; Rollman E; Zuber AK; Rechinsky VO; Rytting AS; Källander CF; Hinkula J; Kochetkov SN; Liu M; Wahren B
Vaccine; 2004 Apr; 22(13-14):1810-9. PubMed ID: 15068865
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress induced by HIV-1 reverse transcriptase modulates the enzyme's performance in gene immunization.
Isaguliants M; Smirnova O; Ivanov AV; Kilpelainen A; Kuzmenko Y; Petkov S; Latanova A; Krotova O; Engström G; Karpov V; Kochetkov S; Wahren B; Starodubova E
Hum Vaccin Immunother; 2013 Oct; 9(10):2111-9. PubMed ID: 23881028
[TBL] [Abstract][Full Text] [Related]
7. Fusion to Flaviviral Leader Peptide Targets HIV-1 Reverse Transcriptase for Secretion and Reduces Its Enzymatic Activity and Ability to Induce Oxidative Stress but Has No Major Effects on Its Immunogenic Performance in DNA-Immunized Mice.
Latanova A; Petkov S; Kuzmenko Y; Kilpeläinen A; Ivanov A; Smirnova O; Krotova O; Korolev S; Hinkula J; Karpov V; Isaguliants M; Starodubova E
J Immunol Res; 2017; 2017():7407136. PubMed ID: 28717654
[TBL] [Abstract][Full Text] [Related]
8. A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity.
Hallengärd D; Wahren B; Bråve A
Viral Immunol; 2013 Apr; 26(2):163-6. PubMed ID: 23573980
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
10. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
[TBL] [Abstract][Full Text] [Related]
12. Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines.
Singh RA; Barry MA
J Immunol; 2004 Oct; 173(7):4387-93. PubMed ID: 15383568
[TBL] [Abstract][Full Text] [Related]
13. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
Smith JM; Amara RR; Campbell D; Xu Y; Patel M; Sharma S; Butera ST; Ellenberger DL; Yi H; Chennareddi L; Herndon JG; Wyatt LS; Montefiori D; Moss B; McClure HM; Robinson HL
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1335-47. PubMed ID: 15650426
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
15. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
[TBL] [Abstract][Full Text] [Related]
16. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
[TBL] [Abstract][Full Text] [Related]
17. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
[TBL] [Abstract][Full Text] [Related]
18. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses.
Bolhassani A; Kardani K; Vahabpour R; Habibzadeh N; Aghasadeghi MR; Sadat SM; Agi E
Immunol Lett; 2015 Dec; 168(2):366-73. PubMed ID: 26518142
[TBL] [Abstract][Full Text] [Related]
19. DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge.
Isaguliants MG; Petrakova NN; Zuber B; Pokrovskaya K; Gizatullin R; Kostyuk DA; Kjerrström A; Winberg G; Kochetkov SN; Hinkula J; Wahren B
Intervirology; 2000; 43(4-6):288-93. PubMed ID: 11251384
[TBL] [Abstract][Full Text] [Related]
20. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
